Following on from our hugely successful sold-out event in March, Canary Wharf Life Sciences and Level39 are excited to announce the second edition of Fin | Tech | Bio at Canary Wharf, a leading gathering for the life sciences, fintech, and techbio community. Taking place on Tuesday, 14 October, from 5:30pm – 8:00pm at Level39, Canary Wharf.

Expect thought-provoking discussions, meaningful connections, and the opportunity to engage with the growing Canary Wharf life sciences and tech ecosystem.

Fin|Tech|Bio at Canary Wharf: Synthetic vs Real World Data (RWD) details

• Date: Tuesday, 14th October
• Time: 5:30pm – 8:00pm
• Organisers: Canary Wharf Life Sciences & Level39
• Venue: Level39, One Canada Square, Canary Wharf, London E14 5AB

About the speakers

Full speaker line-up will be announced shortly and will include experts from:

• CPRD MHRA
• Genomics England
• LifeArc
• AxonJay

These speakers bring deep expertise across life sciences, health data, synthetic data generation, and AI-driven innovation.

About Fin|Tech|Bio at Canary Wharf

Fin|Tech|Bio is a collaborative event series exploring the convergence of biotech/techbio, finance, and technology.

Synthetic data is rapidly transforming how sensitive and complex data is accessed, analysed, and shared across sectors. In this second edition, our experts will explore the growing role of synthetic data in life sciences and finance applications – two industries where data privacy, regulatory compliance, and model robustness are paramount. Discussions will also delve into the advantages and limitations of Real World Data versus Synthetic Data.

This event is ideal for:

• Founders, innovators, and startups in healthtech, techbio, fintech, and AI/tech
• Investors exploring the frontier of data innovation
• Regulators, data scientists, and research professionals

Key takeaways from Fin|Tech|Bio at Canary Wharf

• Understand how synthetic data is reshaping life sciences and finance
• Gain insight into regulatory considerations and compliance challenges
• Compare the benefits and limitations of Real World Data vs Synthetic Data
• Connect with innovators, investors, and policymakers shaping the future of data-driven industries
• Learn from case studies presented by leading organisations in the field

About Level39

Level39 is a melting pot of innovators, investors, industry experts, and ambitious entrepreneurs, pioneering change across sectors that impact daily life – FinTech, Cyber Security, Data & AI, GreenTech, Life Sciences, and more.

Our flexible coworking spaces, private offices, and ecosystem programmes provide members with the resources and connections they need to grow into world-leading businesses with major financial and social impact.

Stay connected with upcoming events, news, and insights by subscribing to the Level39 monthly newsletter.

About Canary Wharf Group Life Sciences

Canary Wharf Life Sciences is building a globally recognised life science ecosystem in East London. Already home to over 40 life sciences and healthcare companies – from MHRA and Genomics England to high-growth innovators like Myricx, Cytospire, and IMU Biosciences – the area boasts 100,000 sq ft of occupied CL2/CL3 laboratory and office space.

Laboratory and office space is available now, with One North Quay set to open in Q1 2028 in partnership with Kadans Science Partner, becoming Europe’s largest and most technically advanced commercial life science building.

Canary Wharf Group is the developer of Europe’s largest urban regeneration project, managing and owning approximately 8 million sq ft of office space, 1.1 million sq ft of retail, and over 2,200 apartments.

Stay connected with the latest developments by subscribing to the Canary Wharf Life Sciences Bimonthly Newsletter.